Patient-reported outcomes using a wearable cardioverter-defibrillator: results from a systematic review
International Journal of Technology Assessment in Health Care · 2023
DOI: 10.1017/s0266462322003300 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Technology Assessment in Health Care, 2023. Verfasst von Pamela Aidelsburger und 2 weiteren Autor:innen. Beteiligte Einrichtung: CAREM GmbH, Königsdorf, Germany. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Wearable Electronic Devices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
The aim of this study was to assess the effect of the wearable cardioverter-defibrillator (WCD) on patient-reported outcomes (PRO) in adult patients with high risk for sudden cardiac arrest.
Methods
We performed a systematic literature search in Medline (via PubMed) and Cochrane Library in February 2022 and included studies with a study population ≥18 years and prescribed WCD. PRO include health-related quality of life (QoL), symptoms, utilities, or satisfaction ratings. Study selection was done by two reviewers independently using predefined inclusion and exclusion criteria. Quality assessment of studies as well as data extraction was performed by one author and approved by a second author. Results of the included studies are presented quantitatively.
Results
One randomized controlled trial (RCT), one comparative non-randomized trial, and three single-arm trials were included. QoL was assessed in four studies, but with different assessment tools. One study additionally evaluated the change in depressive symptoms and anxiety and one study focused on acceptability of WCD but evaluated items that are closely related to QoL. Results of the RCT show no statistically significant difference in QoL assessed by SF-36 and EQ-5D comparing WCD and Guideline-Directed Medical Therapy (GDMT) versus GDMT alone. One comparative study reports an improvement in depressive symptoms and anxiety within groups but no significant difference between groups. Further, one single-arm study reported improvement in QoL between baseline and day 90 and day 180.
Conclusions
The available evidence demonstrates that the usage of WCD is not affecting PRO, like QoL, depressive symptoms or anxiety negatively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CAREM GmbH, Königsdorf, Germany.
- Medical University of Vienna, Vienna, Austria.
- Favoriten Clinic, Vienna, Austria.
ORCID-Profile: Pamela Aidelsburger
Zitieren
APA
Aidelsburger, P., Seyed-Ghaemi, J., & Bonderman, D. (2023). Patient-reported outcomes using a wearable cardioverter-defibrillator: results from a systematic review. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462322003300
Vancouver
Aidelsburger P, Seyed-Ghaemi J, Bonderman D. Patient-reported outcomes using a wearable cardioverter-defibrillator: results from a systematic review. International Journal of Technology Assessment in Health Care. 2023. doi:10.1017/s0266462322003300
BibTeX
@article{Aidelsburger2023,
author = {Aidelsburger, Pamela and Seyed-Ghaemi, Janine and Bonderman, Diana},
title = {Patient-reported outcomes using a wearable cardioverter-defibrillator: results from a systematic review},
journal = {International Journal of Technology Assessment in Health Care},
year = {2023},
doi = {10.1017/s0266462322003300}
}
EUVIMED